EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Quinoxalinone‐based, endoplasmic reticulum‐targeting photosensitizer nanoparticles for tumor photodynamic therapy

Chao Sun, Lici Wang, Tao Li, Lei Duan, Yan Dong, Ji Li

Bioengineering & Translational Medicine · 2026-11 · 11 (6)

DOI: 10.1002/btm2.70170 ↗
AbstractBibliografische Angaben

Abstract

Abstract The endoplasmic reticulum (ER) is an indispensable organelle responsible for the synthesis and transport of proteins and membrane lipids, playing a critical role in numerous physiological and pathological processes. Leveraging the properties of the ER, we developed novel quinoxalinone‐based, ER‐targeting photosensitizer nanoparticles (Qui‐PS NPs) by conjugating an ER‐specific targeting peptide(RACR) and evaluated their photodynamic therapy (PDT) efficacy. The size, morphology, cellular uptake, ER targeting capability, cell viability, biodistribution, and antitumor efficacy were assessed using dynamic light scattering, transmission electron microscopy, confocal microscopy, CCK‐8 assay, ICP‐Mass spectrometry, and tumor volume measurements, respectively. The results demonstrated that the synthesized Qui‐PS NPs possessed an average diameter of nm, a polydispersity index (PDI) of , and a Zeta potential of mV. These nanoparticles exhibited near‐infrared fluorescence emission centered at 830 nm and demonstrated superior singlet oxygen ( 1 O 2 ) generation capability. The NPs were readily internalized by MCF‐7 cells, displayed specific ER targeting, and induced cytotoxic effects upon light irradiation, with an value of μg/mL. In tumor‐bearing mice, Qui‐PS NPs preferentially accumulated in tumor tissue and significantly suppressed tumor progression under light irradiation, with minimal impact on body weight. These findings suggest that these ER‐targeted NPs represent a promising nanoplatform for potential application in tumor PDT.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →